Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iRadimed Corporation - Common Stock (NQ:IRMD)

96.86 +0.63 (+0.65%)
Streaming Delayed Price Updated: 2:33 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about iRadimed Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
IRadimed (IRMD) Q3 2025 Earnings Call Transcript ↗
IRadimed (IRMD) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Iradimed (IRMD) CEO Sold 5,000 Shares Worth $413,216 ↗
Iradimed (IRMD) CEO Sold 5,000 Shares Worth $413,216 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
IRADIMED CORP (NASDAQ:IRMD) Reports Strong Q3 2025 Earnings, Beats Estimates and Raises Guidance ↗
Iradimed (IRMD) beat Q3 2025 earnings and revenue estimates, achieving record sales. The MRI device specialist also raised its full-year 2025 guidance, signaling strong momentum. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Preview: iRadimed's Earnings ↗
 
Via Benzinga
News headline image
US Market's Undiscovered Gems: Three Promising Stocks Poised for Investor Attention
In a financial landscape often dominated by mega-cap technology giants and established blue-chip companies, astute investors are continuously on the hunt for "undiscovered gems"—smaller, often... 
Via MarketMinute
News headline image
Earnings Preview: iRadimed ↗
Via Benzinga
News headline image
Iradimed (IRMD) Q2 Revenue Jumps 14% ↗
Via The Motley Fool
News headline image
IRADIMED CORP (NASDAQ:IRMD) Reports Record Q2 2025 Earnings, Raises Full-Year Guidance Amid Strong Market Rally ↗
IRADIMED CORP (IRMD) reported record Q2 2025 earnings, beating estimates with $20.4M revenue and $0.49 EPS. Shares surged 6.27% pre-market as the company raised full-year guidance. 
Via Chartmill
News headline image
Earnings Scheduled For August 1, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing? ↗
A fundamental analysis of (NASDAQ:IRMD): Why IRADIMED CORP (NASDAQ:IRMD) qualifies as a quality stock. 
Via Chartmill
News headline image
IRADIMED CORP (NASDAQ:IRMD) – A Quality Stock Worth Considering ↗
IRADIMED CORP (NASDAQ:IRMD) is a financially strong, debt-free company with high profitability and growth potential, making it a compelling choice for quality investors. 
Via Chartmill
News headline image
IRadimed Corp (NASDAQ:IRMD) – A Quality Stock Worth Considering ↗
IRadimed Corp (NASDAQ:IRMD) is a debt-free, high-ROIC medical device company with strong profitability and cash flow, making it a candidate for quality investors. 
Via Chartmill
News headline image
Why IRADIMED CORP (NASDAQ:IRMD) should be investigated by quality investors. ↗
A fundamental analysis of (NASDAQ:IRMD): Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing? 
Via Chartmill
News headline image
Intuitive Surgical Gets Rating Upgrade. No. 1 In Its Industry; Profits, Sales Climbing. ↗
Intuitive Surgical, No. 1 stock in its group, has a deep moat around its technology and has sold is robotic surgical systems for 30 years. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Reasonable Growth, Debt Levels, and a High ROIC Make IRADIMED CORP (NASDAQ:IRMD) Appealing to Quality Investors. ↗
Why the quality investor may take a look at IRADIMED CORP (NASDAQ:IRMD). 
Via Chartmill
News headline image
Exploring NASDAQ:IRMD's quality characteristics. ↗
Reasonable growth and debt and a high ROIC for IRADIMED CORP (NASDAQ:IRMD). 
Via Chartmill
News headline image
Earnings Scheduled For February 8, 2024 ↗
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
News headline image
iRadimed's Earnings Outlook ↗
 
Via Benzinga
News headline image
Wednesday Is Your Last Chance To Buy iRadimed Before The Dividend Payout ↗
 
Via Benzinga
News headline image
Masimo Stock Gets Relative Strength Rating Upgrade ↗
The Relative Strength Rating for Masimo stock jumped into a higher percentile Tuesday, as it got a lift from 69 to 78. 
Via Investor's Business Daily
News headline image
IRMD Stock Earnings: iRadimed Beats EPS, Beats Revenue for Q1 2024 ↗
IRMD stock results show that iRadimed beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Bruker Stock Rising, Near Buy Point; Gets Rating Upgrade ↗
A Relative Strength Rating upgrade for Bruker stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
iRadimed's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Caleres, Cloudflare And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by more than 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Should you consider NASDAQ:IRMD for quality investing? ↗
Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing? 
Via Chartmill
News headline image
iRadimed: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2023 ↗
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.